Literature DB >> 26330489

Systemic PPARγ deletion causes severe disturbance in fluid homeostasis in mice.

Li Zhou1, Alexandra Panasiuk2, Maicy Downton2, Daqiang Zhao2, Baoxue Yang3, Zhanjun Jia2, Tianxin Yang4.   

Abstract

The pharmacological action of peroxisome proliferator-activated receptor (PPAR)γ in promoting sodium and water retention is well documented as highlighted by the major side-effect of body weight gain and edema associated with thiazolidinedione use. However, a possible physiological role of PPARγ in regulation of fluid metabolism has not been reported by previous studies. Here we analyzed fluid metabolism in inducible whole-body PPARγ knockout mice. The null mice developed severe polydipsia and polyuria, reduced urine osmolality, and modest hyperphagia. The phenomenon persisted during 3 days of pair feeding and pair drinking, accompanied by progressive weight loss. After 24 h water deprivation, the null mice had a lower urine osmolality, a higher urine volume, a greater weight loss, and a greater rise in hematocrit than the floxed control. Urinary vasopressin (AVP) excretion was not different between the genotypes under basal condition or after WD. The response of urine osmolality to acute and chronic 1-desamino-8-D-arginine vasopressin treatment was attenuated in the null mice, but the total abundance or phosphorylation of aquaporin 2 (AQP2) in the kidney or AVP-induced cAMP production in inner medullary collecting duct suspensions was unaffected. Overall, PPARγ participates in physiological control of fluid homeostasis through an unknown mechanism involving cAMP/AQP2-independent enhancement of AVP response.

Entities:  

Keywords:  kidney; peroxisome proliferator-activated receptor; vasopressin

Mesh:

Substances:

Year:  2015        PMID: 26330489      PMCID: PMC4629006          DOI: 10.1152/physiolgenomics.00066.2015

Source DB:  PubMed          Journal:  Physiol Genomics        ISSN: 1094-8341            Impact factor:   3.107


  34 in total

1.  Collecting duct-specific knockout of adenylyl cyclase type VI causes a urinary concentration defect in mice.

Authors:  Karl P Roos; Kevin A Strait; Kalani L Raphael; Mitsi A Blount; Donald E Kohan
Journal:  Am J Physiol Renal Physiol       Date:  2011-09-21

2.  Fluid retention mediated by renal PPARgamma.

Authors:  Bart Staels
Journal:  Cell Metab       Date:  2005-08       Impact factor: 27.287

Review 3.  PPARgamma in immunity and inflammation: cell types and diseases.

Authors:  Lajos Széles; Dániel Töröcsik; László Nagy
Journal:  Biochim Biophys Acta       Date:  2007-02-24

4.  Pattern of sodium excretion accompanying starvation.

Authors:  P R Boulter; R S Hoffman; R A Arky
Journal:  Metabolism       Date:  1973-05       Impact factor: 8.694

5.  Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention.

Authors:  Hui Zhang; Aihua Zhang; Donald E Kohan; Raoul D Nelson; Frank J Gonzalez; Tianxin Yang
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-14       Impact factor: 11.205

6.  Adipose-specific effect of rosiglitazone on vascular permeability and protein kinase C activation: novel mechanism for PPARgamma agonist's effects on edema and weight gain.

Authors:  Konstantinos B Sotiropoulos; Allen Clermont; Yutaka Yasuda; Christian Rask-Madsen; Motonobu Mastumoto; Junichi Takahashi; Kim Della Vecchia; Tatsuya Kondo; Lloyd P Aiello; George L King
Journal:  FASEB J       Date:  2006-05-03       Impact factor: 5.191

7.  Vasopressin-stimulated increase in phosphorylation at Ser269 potentiates plasma membrane retention of aquaporin-2.

Authors:  Jason D Hoffert; Robert A Fenton; Hanne B Moeller; Brigitte Simons; Dmitry Tchapyjnikov; Bradley W McDill; Ming-Jiun Yu; Trairak Pisitkun; Feng Chen; Mark A Knepper
Journal:  J Biol Chem       Date:  2008-07-07       Impact factor: 5.157

8.  PPARgamma in the endothelium regulates metabolic responses to high-fat diet in mice.

Authors:  Takeshi Kanda; Jonathan D Brown; Gabriela Orasanu; Silke Vogel; Frank J Gonzalez; Juliano Sartoretto; Thomas Michel; Jorge Plutzky
Journal:  J Clin Invest       Date:  2008-12-08       Impact factor: 14.808

Review 9.  PPARγ signaling and metabolism: the good, the bad and the future.

Authors:  Maryam Ahmadian; Jae Myoung Suh; Nasun Hah; Christopher Liddle; Annette R Atkins; Michael Downes; Ronald M Evans
Journal:  Nat Med       Date:  2013-05-07       Impact factor: 53.440

10.  The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases.

Authors:  Sandeep Tyagi; Paras Gupta; Arminder Singh Saini; Chaitnya Kaushal; Saurabh Sharma
Journal:  J Adv Pharm Technol Res       Date:  2011-10
View more
  3 in total

Review 1.  Nuclear Receptor Regulation of Aquaporin-2 in the Kidney.

Authors:  Xiao-Yan Zhang; Bing Wang; You-Fei Guan
Journal:  Int J Mol Sci       Date:  2016-07-11       Impact factor: 5.923

Review 2.  Current Advances in the Biochemical and Physiological Aspects of the Treatment of Type 2 Diabetes Mellitus with Thiazolidinediones.

Authors:  D Alemán-González-Duhart; F Tamay-Cach; S Álvarez-Almazán; J E Mendieta-Wejebe
Journal:  PPAR Res       Date:  2016-05-23       Impact factor: 4.964

Review 3.  PPARγ and Its Agonists in Chronic Kidney Disease.

Authors:  Yuhua Ma; Manman Shi; Yuxin Wang; Jian Liu
Journal:  Int J Nephrol       Date:  2020-02-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.